Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Announces Update on FDA New Drug Application for Ketamine

GlobeNewswire 5 days ago

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

GlobeNewswire 11 days ago

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

GlobeNewswire 12 days ago

PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

GlobeNewswire October 23, 2024

PharmaTher Announces Update on FDA New Drug Application for Ketamine

GlobeNewswire September 4, 2024

PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Newsfile August 28, 2024

PharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins

GlobeNewswire August 21, 2024

PharmaTher's Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

GlobeNewswire August 19, 2024

PharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

GlobeNewswire May 15, 2024

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

Jocelyn Aspa May 10, 2024

PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire May 10, 2024

PharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

GlobeNewswire May 1, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire April 18, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire April 16, 2024

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

GlobeNewswire April 2, 2024

PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

GlobeNewswire February 21, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire February 12, 2024

PharmaTher Provides Update for Expected FDA Approval of Ketamine

GlobeNewswire January 10, 2024

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

GlobeNewswire September 27, 2023

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX(TM) (Ketamine) to the FDA

GlobeNewswire September 6, 2023